Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dan Gold’s Hedge Fund Adds Oncothyreon

Dan Gold’s hedge fund: Oncothyreon Inc (USA) (NASDAQ:ONTY) was just added to the equity portfolio of Daniel Gold’s hedge fund QVT Financial. In a filing with the Securities and Exchange Commission, QVT disclosed that it owns almost 3.7 million shares of Oncothyreon, the value of the stake amounting to $6.7 million. Through the acquisition, QVT holds about 5.8% of the company.

Oncothyreon Inc (USA) (NASDAQ:ONTY)

Oncothyreon is a company engaged in production of therapeutic products for the cancer  treatment. The company expanded its net loss to $18 million for the second quarter, from last year’s amount of $8.1 million. At the same time, the company recently appointed the former  Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Dr. Ted W. Love, to its Board of Directors.

Aside from QVT Financial, it is important to mention some other hedge funds who are bullish on Oncothyreon, according to our database. As follows, in the latest round of 13F filings, Israel Englander’s Millennium Management is the hedge fund with the second-largest stake, which involves 2.1 million shares. It is followed by First Eagle Investment Management, which disclosed ownership of 1.3 million shares, and Adage Capital Management, managed by Phill Gross and Robert Atchinson, which owned 950,000 shares at the end of the last quarter. Check back here for more updates on Dan Gold’s hedge fund.

Recommended Reading:

There’s More to Carl Icahn’s Portfolio Than Just Apple and Dell

Warren Buffett Portfolio: How He’s Playing The Small-Caps

Value Investing Congress 2013: Small-Cap ‘Needles in a Haystack’ From Guy Gottfried

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!